Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing

Molecular Carcinogenesis

Volumn 41, Issue 4, 2004, Pages 187-196

  Zerbe, Laura K ^a   Pino, Irene ^b   Pio, Ruben ^b   Cosper, Pippa F ^a   Dwyer Nield, Lori D ^a   Meyer, Amy M ^a   Port, J David ^a   Montuenga, Luis M ^b   Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

3 methylcholanthrene; Alternative splicing; Butylated hydroxytoluene; CD44; Lung cancer

Indexed keywords

BUTYLCRESOL; CD44V ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; MESSENGER RNA; SPLICING FACTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CELL DIVISION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; HYPERPLASIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ADENOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; REGENERATION; RNA PROCESSING; TUMOR GROWTH;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD44; BUTYLATED HYDROXYTOLUENE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HYPERPLASIA; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; PROTEIN ISOFORMS; PROTEIN TRANSPORT; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 9244221107     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20053     Document Type: Article

References (40)

1. Stewart BW, Kleihues P. World Cancer Report. Lyon: IARCPress; 2003.
2. Mercatante D, Kole R. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 2000;85:237-243.
3. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 2002;3:195-205.
4. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003;72:291-336.
5. Graveley BR. Alternative splicing: Increasing diversity in the proteomic world. Trends Genet 2001;17:100-107.
6. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001;29:2850-2859.
7. Wang ZN, Lo HS, Yang H, et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 2003;63:655-657.
8. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: Results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997;3:2237-2246.
9. Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003;41:131-143.
10. Peebles KA, Duncan MW, Ruch RJ, Malkinson AM. Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gjal. Carcinogenesis 2003;24:651-657.
11. Blaxall BC, Dwyer-Nield L, Bauer AK, Bohlmeyer TJ, Malkinson AM, Port JD. Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF-1) and Hu antigen R (HuR), in neoplastic lung tissue. Mol Carcinog 2000;28:76-83.
12. Malkinson AM. Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 2001;32:265-279.
13. Mayeda A, Krainer AR. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 1992;68:365-375.
14. Caceres JF, Stamm S, Helfman DM, Krainer AR. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science 1994;265:1706-1709.
15. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999;18:3574-3582.
16. Cooper DL, Dougherty GJ. To metastasize or not? Selection of CD44 splice sites. Nat Med 1995;1:635-637.
17. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998;58:1108-1110.
18. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
19. Malkinson AM, Koski KM, Evans WA, Festing MF. Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res 1997;57:2832-2834.
20. Malkinson AM. Prevention of butylated hydroxytoluene-induced lung damage in mice by cedar terpene administration. Toxicol Appl Pharmacol 1979;49:551-560.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
22. Malkinson AM, Beer DS. Major effect on susceptibility to urethan-induced pulmonary adenoma by a single gene in BALB/cBy mice. J Natl Cancer Inst 1983;70:931-936.
23. Witschi H, Malkinson AM, Thompson JA. Metabolism and pulmonary toxicity of butylated hydroxytoluene (BHT). Pharmacol Ther 1989;42:89-113.
24. Malkinson AM, Thaete LG, Blumenthal EJ, Thompson JA. Evidence for a role of tert-butyl hydroxylation in the induction of pneumotoxicity in mice by butylated Hydroxytoluene. Toxicol Appl Pharmacol 1989;101:196-204.
25. Adamson IY, Bowden DH, Cote MG, Witschi H. Lung injury induced by butylated hydroxytoluene: Cytodynamic and biochemical studies in mice. Lab Invest 1977;36:26-32.
26. Thaete LG, Gunning WT, Stoner GD, Malkinson AM. Cellular derivation of lung-tumors in sensitive and resistant strains of mice - Results at 28 and 56 weeks after urethane treatment. J Nat Cancer Inst 1987;78:743-749.
27. Ghigna C, Moroni M, Porta C, Riva S, Biamonti G. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res 1998;58:5818-5824.
28. Xiao SH, Manley JL. Phosphorylation of the ASF/SF2 RS domain affects both protein-protein and protein-RNA interactions and is necessary for splicing. Genes Dev 1997;11:334-344.
29. Caceres JF, Screaton GR, Krainer AR. A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev 1998;12:55-66.
30. Boise LH, Gonzalezgarcia M, Postema CE, et al. Bcl-X, A Bcl-2-related gene that functions as a dominant regulator of apoptotic cell-death. Cell 1993;74:597-608.
31. Wang Y, You M, Wang Y. Alternative splicing of the K-ras gene in mouse tissues and cell lines. Exp Lung Res 2001;27:255-267.
32. Katoh M, Kirikoshi H, Saitoh T, Sagara N, Koike J. Alternative splicing of the WNT-2B/WNT-13 gene. Biochem Biophys Res Commun 2000;275:209-216.
33. Orban TI, Olah E. Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem Biophys Res Commun 2001;280:32-38.
34. Lukas J, Gao DQ, Keshmeshian M, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001;61:3212-3219.
35. Jiang ZH, Wu JY. Alternative splicing and programmed cell death. Proc Soc Exp Biol Med 1999;220:64-72.
36. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19:432-441.
37. Thompson TE, Rogan PK, Risinger JI, Taylor JA. Splice variants but not mutations of DNA polymerase beta are common in bladder cancer. Cancer Res 2002;62:3251-3256.
38. Feltes CM, Kudo A, Blaschuk O, Byers SW. An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res 2002;62:6688-6697.
39. Zhu DG, Xu G, Ghandhi S, Hubbard K. Modulation of the expression of p16(INK4a) and p14(ARF) by hnRNP A1 and A2 RNA binding proteins: Implications for cellular senescence. J Cell Physiol 2002;193:19-25.
40. Matter N, Marx M, Weg-Remers S, Ponta H, Herrlich P, Konig H. Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J Biol Chem 2000;275:35353-35360.